Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al
While the high upfront cost of these drugs is a significant barrier, they could represent a significant source of savings in the later years from lower rates of obesity, cardiovascular, and kidney disease
Patients and Methods Ethics Statement This study was approved by the Ethics in Research Committee at the Federal University of Gois under protocol number 195/11 dated 27 th June, 2011 and was conducted according to the Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association Declaration of Helsinki
The FDA issues warning letters requiring the company to cease prohibited marketing claims, reformulate the product, or stop selling it entirely
doi: 10.1093/jee/83.6.2443 201 OmamtE
This suggests that early microvascular impairments may precede overt muscle atrophy, potentially serving as a biomarker for sarcopenia risk